Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 46.25
+0.62 (1.36%)
Feb 3, 2026, 2:35 PM CST
SHE:002294 Revenue
Shenzhen Salubris Pharmaceuticals had revenue of 1.11B CNY in the quarter ending September 30, 2025, with 15.85% growth. This brings the company's revenue in the last twelve months to 4.25B, up 8.76% year-over-year. In the year 2024, Shenzhen Salubris Pharmaceuticals had annual revenue of 4.01B with 19.22% growth.
Revenue (ttm)
4.25B
Revenue Growth
+8.76%
P/S Ratio
11.96
Revenue / Employee
1.18M
Employees
3,596
Market Cap
50.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.01B | 646.89M | 19.22% |
| Dec 31, 2023 | 3.37B | -116.67M | -3.35% |
| Jan 1, 2023 | 3.48B | 423.62M | 13.85% |
| Jan 1, 2022 | 3.06B | 319.83M | 11.68% |
| Dec 31, 2020 | 2.74B | -1.73B | -38.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 43.09B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| China Resources Sanjiu Medical & Pharmaceutical | 29.86B |
| Humanwell Healthcare (Group) | 24.18B |
| Zhejiang NHU Company | 22.47B |
| Beijing Tongrentang | 18.09B |
| Changchun High-Tech Industry (Group) | 12.88B |
| Livzon Pharmaceutical Group | 11.85B |